C3PO Trial


Among all of the many complex functions and uses of our hands, they are often the first point of contact when we fall or crash. We use our hands and wrists to absorb energy after falls or motor vehicle crashes, in an effort to prevent injuries to the head, chest, and abdomen. Although hand and wrist injuries are common, acute carpal dislocations such as perilunate injuries are frequently underestimated, falsely diagnosed and/or underreported. Little is known about the frequency of these devastating injuries. Perilunate spectrum injuries lead to poor wrist function and pain which can jeopardize a person’s ability to accomplish activities of daily living, and reduces their productivity.

This is a uniquely designed study that will be comprehensively monitoring clinically diagnosed perilunate injuries across Canada. A consortium of hand surgeons across the country with research infrastructure has united to support this ambitious trial. Patients can enroll in one of two studies in this project:
1. National injury registry
2. A prospective observational cohort study examining clinical and
functional long-term outcomes

To date, there is not a single thread of prospectively collected data for this common injury pattern. Our team’s goal is to collect all relevant demographic information, injury information, surgical information, and track the healing progress, and recovery for these injuries over a 10 year period.


Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 14 to 150

Inclusion criteria:

1. 14 years of age or older
2. Being treated by a Canadian Orthopaedic Surgeon for a complex wrist injury
3. Has had surgery for the complex wrist injury recently (i.e. in the last 3 months)


Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

South Campus Research Unit for Bone & Soft Tissue (SCRBUS) Team 310265 - 4448 Front Street SE, Calgary, AB Canada T3M 1M4

Principal investigator:

Neil White

Clinical trial: